DNA-testing company 23andMe made headlines last week when it announced that it would share consumers’ anonymized genetic data with pharmaceutical giant GlaxoSmithKline as part of a $300-million deal.
DNA-testing company 23andMe made headlines last week when it announced that it would share consumers’ anonymized genetic data with pharmaceutical giant GlaxoSmithKline as part of a $300-million deal.